Merus B.V.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Merus B.V. sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Merus B.V.: 8 sponsored US clinical trials, 4 recruiting.
Merus B.V. sponsors 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 2 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Head and Neck Squamous Cell Carcinoma, with 4 trials.
Upper-quartile sponsor footprint
Merus B.V. sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
NCT07353957
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
NCT06496178
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT04868877
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
NCT03922204
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
NCT03321981
MCLA-117 in Acute Myelogenous Leukemia
NCT03038230
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Merus B.V. pipeline
4 recruiting of 8 indexed (50% open); 2 completed (25%).
Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Head and Neck Squamous Cell Carcinoma (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Merus B.V.: open-pipeline peers nationwide
Peers matched on 8 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Merus B.V. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
Related
What to do with this Merus B.V. page
8 registered trials is a research-attention snapshot, not an endorsement of Merus B.V. or any single study.
- 4 of Merus B.V.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Head and Neck Squamous Cell Carcinoma is the condition Merus B.V. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Head and Neck Squamous Cell Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Merus B.V. pipeline card: 8 registered trials from official public datasets.Report a data error.